Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Surface Oncology, Inc. (SURF : NSDQ)
 
 • Company Description   
Surface Oncology, Inc. is a clinical-stage immuno-oncology company. It develops therapies for the treatment of cancer. The company's product pipeline includes CD47, CD73, SRF231, SRF373, SRF617, SRF388 and SRF231 which are in clinical stage. Surface Oncology is based in Cambridge, Massachusetts.

Number of Employees: 60

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.76 Daily Weekly Monthly
20 Day Moving Average: 235,364 shares
Shares Outstanding: 60.72 (millions)
Market Capitalization: $46.24 (millions)
Beta: 1.68
52 Week High: $2.15
52 Week Low: $0.56
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 31.86% 26.87%
12 Week 2.96% -4.42%
Year To Date -7.13% -15.53%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
50 HAMPSHIRE STREET 8TH FLOOR
-
CAMBRIDGE,MA 02139
USA		 ph: 617-714-4096
fax: -		 syoung@surfaceoncology.com http://www.surfaceoncology.com
 
 • General Corporate Information   
Officers
Robert W. Ross - Chief Executive Officer
Denice Torres - Chairman of the Board
Jessica Fees - Chief Financial Officer
Carsten Brunn - Director
J. Jeffrey Goater - Director

Peer Information
Surface Oncology, Inc. (BJCT)
Surface Oncology, Inc. (CADMQ)
Surface Oncology, Inc. (APNO)
Surface Oncology, Inc. (UPDC)
Surface Oncology, Inc. (IMTIQ)
Surface Oncology, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 86877M209
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/02/23
Share - Related Items
Shares Outstanding: 60.72
Most Recent Split Date: (:1)
Beta: 1.68
Market Capitalization: $46.24 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.37 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.61
Price/Cash Flow: -
Price / Sales: 1.49
EPS Growth
vs. Year Ago Period: -353.85%
vs. Previous Quarter: 5.71%
Sales Growth
vs. Year Ago Period: 1,745.02%
vs. Previous Quarter: 19,380.52%
ROE
03/31/23 - -87.82
12/31/22 - -53.11
09/30/22 - -52.58
ROA
03/31/23 - -53.25
12/31/22 - -33.77
09/30/22 - -33.82
Current Ratio
03/31/23 - 7.27
12/31/22 - 7.94
09/30/22 - 8.34
Quick Ratio
03/31/23 - 7.27
12/31/22 - 7.94
09/30/22 - 8.34
Operating Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Net Margin
03/31/23 - -
12/31/22 - -
09/30/22 - -
Pre-Tax Margin
03/31/23 - -
12/31/22 - -211.95
09/30/22 - -219.88
Book Value
03/31/23 - 1.25
12/31/22 - 1.54
09/30/22 - 1.86
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.30
12/31/22 - 0.27
09/30/22 - 0.23
Debt-to-Capital
03/31/23 - 22.87
12/31/22 - 21.50
09/30/22 - 18.41
 

Powered by Zacks Investment Research ©